In April 2010, the FDA approved sipuleucel-T for patients with castration-resistant and metastatic prostate cancer, providing a new treatment that would help the body fight its own cancer.
Sandra Kelly, RN, MS, NP, Nurse Practitioner Brigham & Women’s Hospital
Advertisement
Articles by Sandra Kelly, RN, MS, NP, Nurse Practitioner Brigham & Women’s Hospital
Advertisement
Latest Updated Articles
Immunotherapy: Personalized Treatment for Advanced Prostate CancerPublished: September 19th 2012 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5